Sign Out
Because Simulect is an immunoglobulin, no metabolic drug-drug interactions are to be expected.
Human antimurine antibody (HAMA) responses in Simulect-treated patients are rare (3.5%). The use of Simulect does not preclude subsequent treatment with murine antilymphocyte antibody preparations.
Incompatibilities: No known incompatibilities.
